37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 13-15, 2021
H. Ganjgahi et al.
Objective: Evaluate the effect of ofatumumab on the percentage whole brain volume change (PBVC) over 2 years vs. with historical placebo.
Data source: Ofatumumab data from the ASCLEPIOS I/II trials (n=703) and placebo data from the FREEDOMS and FREEDOMS II trials of fingolimod (n=543).
- PBVC was lower with ofatumumab vs. placebo over one year (-0.57% vs -0.58%) and over two years (-1.00% vs -1.25%).
- The treatment effect of ofatumumab was more apparent in patients with a higher T2 lesion volume at baseline.
Conclusion: Ofatumumab significantly reduced brain volume loss.
See also P982 – Outcomes of COVID-19 in patients with relapsing multiple sclerosis receiving ofatumumab: data from the ALITHIOS study and post marketing surveillance Anne H. Cross (St. Louis, United States)
G. Giovannoni et al.
Objective: To evaluate the long-term efficacy of ocrelizumab.
Data source: 5.5-year data from the open-label extension of the OPERA I /II trials.
- 3% of patients entering the extension completed extension year 5.5.
- Annualized relapse rate remained low in patients on continuous ocrelizumab (0.03 at extension year 5.5).
- ARR decreased in the interferon group after switching to ocrelizumab (0.032 at extension year 5.5).
- The rate of 48-week confirmed disability progression was lower in the continuous ocrelizumab group vs. the IFN/OCR group at extension year 5.5 (17.9% vs 21.5%, NS).
- The proportion requiring a walking aid was lower in the OCR-OCR vs. IFN-OCR group at extension year 5.5 (6.6% vs 9.5%, NS).
Conclusion: Patients who switched from IFN β-1a to ocrelizumab experienced a rapid and robust reduction in ARR that was maintained through the 5.5-year follow-up.
B. Cree et al.
Objective: Examine the long-term efficacy of siponimod in SPMS.
Data source: Data from the long-term extension of the phase III EXPAND trial with a corrected virtual placebo.
- The risk of 6-month confirmed disability progression was reduced 33% with siponimod vs. virtual placebo; median time to 6-month CDP was prolonged by 62%.
- In the subgroup with active disease, the risk of 6-month CDP was reduced 42% with siponimod vs. virtual placebo; median time to 6-month CDP was prolonged by 79%.
- In the subgroup with non-active disease, the risk of 6-month CDP was reduced 20% with siponimod vs. virtual placebo; median time to 6-month CDP was prolonged by 44%.
Conclusion: Siponimod showed sustained efficacy in reducing the risk of progression and prolonging the time to 6-month CDP.
L. Prosperini et al.
Objective: To analysis COVID-19-related mortality in MS patients.
Data source: Meta-analysis of published studies (n=60) reporting COVID-19 mortality (n=5474 patients).
- The crude COVID mortality rate in MS patients was 3.1%.
- Death rates were higher in studies of patients with comorbidities, progressive disease or receiving treatment with anti-CD20 therapies.
- Treatment with an interferon-beta or teriflunomide appeared to have a protective effect.
Conclusions: People with MS have a 24% higher risk of death from COVID-19 than the general population.
Also watch for Late Breaking News:
- P961 – Influence of disease modifying treatment and anti-CD20 infusion timing on humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients Giulio Disanto (Switzerland)
- P978 – COVID-19 in patients with multiple sclerosis despite SARS-CoV-2 vaccination Ahmad Z Mahadeen (United States)
- P979 – Impact of MS disease-modifying therapies on antibody and T cell responses following COVID-19 vaccination Joseph Sabatino (San Francisco, United States)